越来越多玩家加入PI3Kα -H1047R赛道:
$Recursion(RXRX)$ 公布了REC-7735的新临床前疗效数据,这是一种潜在的同类最佳PI3Kα H1047R抑制剂,REC-7735对H1074R突变型的选择性是野生型PI3Kα的100倍以上。
$Cogent Biosciences(COGT)$ started a phase 1 study with its contender, CGT6297, a new listing on clinicaltrials.gov reveals.CGT6297 selectively inhibits PI3Kα H1047R and the 542/545 helical mutants. CGT6297 is >30x selective for PI3Kα H1047R.